However, the authors concluded that PNPLA3-I148M is a loss-of-function mutation rather than neomorphic, the former of which is inconsistent with both mouse and human data pointing to PNPLA3-I148M protein as a driver of MASLD. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.